DelveInsight Forecasts 2.4% CAGR Growth for Anal Cancer Market by 2034 

Anal cancer treatments are seeing a surge, thanks to rising diagnosis rates, more public awareness and better therapies hitting the scene. In 2023, the total number of new anal cancer cases across the seven major markets clocked in at around 20,000. And don’t expect that figure to hold steady—the numbers are projected to climb at about 2.4% per year through 2034.

In USA, DelveInsight’s data points to most cases turning up in the early, localized (Stage I ) category. Regional cases (Stage II and III) come next, while cases that have already spread far and wide (Stage IV) make up the smallest group. In the US, HPV is a key factor, linked to approximately 82% of cases, making it the primary driver behind these statistics.

Anal cancer isn’t a major player in the world of gastrointestinal cancers—just around 2.5% of the total share. Still, its numbers have been ticking upward over the last few decades. The data shows women are more frequently diagnosed than men and the typical age range lands between 45 and 75.

Drilling down, Anal Squamous Cell Carcinoma (ASCC) makes up the majority - roughly 80 to 85% of all Anal cancer cases. The other types - adenocarcinomas, melanomas, basal cell carcinomas - are much less common and represent a smaller portion of the overall picture.

Incyte has secured FDA approval for its PD-1 inhibitor, Zynyz, targeting advanced anal cancer—a notable development in immunotherapy. This approval positions Incyte as a key player in a rapidly evolving market.

Competition is heating up with major pharmaceutical companies like Merck, BioMimetix, Novartis, and Bicara Therapeutics all advancing their own therapies to capture market share. The industry as a whole is shifting toward more personalized and less toxic treatment options, setting higher expectations for both efficacy and safety. This creates substantial opportunities but also raises the bar for any new market entrants.

At present, combination chemoradiotherapy remains the standard first-line therapy. Intensity-modulated radiotherapy (IMRT) is widely adopted to minimize radiation-related side effects, reflecting ongoing improvements in patient care.

Immunotherapy - particularly immune checkpoint inhibitors - is gaining momentum in the treatment of squamous cell carcinoma of the anus. There is active research in both metastatic and locoregional contexts, signaling expanding clinical applications.

Looking forward, the market is projected to see significant growth by 2034. This trajectory is fueled by ongoing technological advancements, improved screening programs, and a favorable regulatory environment. The landscape is becoming increasingly competitive and innovation-driven.

DelveInsight just rolled out their latest report, Anal Cancer Market Insight, Epidemiology, and Market Forecast – 2034. If you’re serious about understanding who’s going to lead the anal cancer market in the next decade, this report’s about as essential as it gets. We’re talking detailed breakdowns of treatment guidelines across different countries, a deep dive into patient demographics, and forecasts that actually help you spot where the big opportunities are hiding.

They’ve covered all the bases: new cases by year, splits by gender, age, cancer subtypes, HPV status, cancer stage—you name it, they’ve analyzed it. There’s even data about how patients move through different lines of treatment. It’s not just a data dump; it’s a playbook for anyone looking to make strategic moves in this market.

You’re getting a full 10-year outlook, comprehensive coverage of the seven major markets (the so-called 7MM), and smart insights on how emerging drugs are performing. There’s competitive analysis, expert opinions, and a no-nonsense look at access and reimbursement hurdles.

If you’re operating in the Anal Cancer space and want to make informed business decisions, this report gives you the clarity and context you need. Stay ahead of market shifts, understand patient journeys, and get a read on what key opinion leaders are forecasting. Download the report and position yourself for success in the evolving anal cancer therapeutics market.

Found this post helpful ? Spread the word by sharing it with friends, on social media or in your group chat. Let’s keep the conversation going!